Lead Product(s) : SAN711
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial
Details : The primary objective of the study is to determine the tolerability and the maximum tolerated dose of SAN711, as evaluated through the single ascending dose and multiple ascending dose phases of the study.
Product Name : SAN711
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2022
Lead Product(s) : SAN711
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SAN711
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Saniona Initiates Phase 1 Clinical Trial of SAN711
Details : The primary objective of the study is to determine the tolerability and the maximum tolerated dose of SAN711, which will be evaluated through single ascending dose and multiple ascending dose phases of the study.
Product Name : SAN711
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2021
Lead Product(s) : SAN711
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable